RSY Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index

Recom Managed Systems, Inc. (AMEX: RSY), a life-sciences company developing patented heart-monitoring technology, announced today that Rajiv Singh, a systems engineer with more than 25 years of experience in business development, program management and infrastructure, container, and port security technology, has signed on as a consultant to the company. "Rajiv's impressive background in engineering and business development for some of the leading technology companies in the world make him an ideal fit for Recom," said Pamela Bunes, Recom's president and chief executive officer. "His counsel and dedicated support will be of tremendous benefit as we continue to advance the company's proprietary technology." In his role at Recom, Mr. Singh will identify additional applications for Recom's biomedical signal-processing platform and guide the progress of the Model 100 Heart Monitor from the research-and-development phase through the contract manufacturing process and into market commercialization. Mr. Singh also will help facilitate interdepartment communications to ensure that clinician feedback is integrated into future Recom products. "Recom has developed a ground-breaking technology with the potential to revolutionize the practice of cardiac monitoring," said Mr. Singh. "I look forward to the opportunity to work with the company at this exciting phase, as we prepare to bring the Model 100 to market." Most recently, Mr. Singh was director of business development for L3 Communications, where he was responsible for expanding the company's programs in critical infrastructure, container and waterside/port security. He has also held positions with Logicon Syscon and Earth Tech. He holds master's degrees in computer science and management from Johns Hopkins University and a master's degree in engineering from Southern Illinois University. Mr. Singh lives in Ellicott City, Md. Breakthrough ECG Monitoring Technology Recom's first product, the Model 100 Heart Monitor, is an ambulatory patient heart monitor that uses patented signal-processing technology to record a clinical-quality ECG signal in the presence of "noise," or interference, generated by the patient's body movements and ambient environment. By reducing these interfering factors during recordings, the Recom Model 100 helps family practitioners, internists and cardiologists more accurately detect cardiac abnormalities or changes that may occur during daily activities and allows medical experts to collect extensive, continuous cardiac data over time, which can establish a baseline against which future readings can be compared. The Model 100 provides up to 48 hours of real-time heart monitoring during patients' everyday activities. The Model 100 has received 510(k) clearance from the Food and Drug Administration (FDA). About Recom Managed Systems, Inc. Recom Managed Systems, Inc. is an emerging life-sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Recom Managed Systems, Inc. uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. With our patented signal-technology platform, Recom brings clinical-quality physiological signal monitoring to the ambulatory setting. Recom Managed Systems, Inc. is traded on the American Stock Exchange under the symbol RSY. More information is located at http://www.recom-systems.com. Caution Regarding Forward-Looking Statements Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Recom's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom's products or services, adverse equity-market conditions and declines in the value of Recom's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom's filings with the Securities and Exchange Commission.